We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

News · September 13, 2021

ERS 2021: NVALT 17 Suggests Possible Benefit of Adding Cisplatin-Pemetrexed to First-Line Erlotinib for Non–Small Cell Lung Cancer

Low study power and high treatment toxicity means search for better combination tyrosine kinase inhibitor treatments will continue

PracticeUpdate Editorial Team

 

Further Reading